

## Thrombocytosis

### Definition

Platelet count  $>450 \times 10^9/l$

### Causes

Thrombocytosis may be due to a primary bone marrow condition or a secondary reactive cause.

**Table 1 Common causes of thrombocytosis**

Primary	Secondary/ Reactive
Myeloproliferative Neoplasm (MPN) <ul style="list-style-type: none"> <li>• Chronic myeloid leukaemia (CML)</li> <li>• Polycythaemia rubra vera, (PRV)</li> <li>• Primary myelofibrosis (PMF)</li> <li>• Essential thrombocythaemia (ET)</li> </ul> Myelodysplastic syndrome(MDS) with del(5q) MDS/MPN overlap syndromes <ul style="list-style-type: none"> <li>• CMML</li> <li>• RARS-T</li> <li>• MDS/MPN-U</li> </ul>	<ul style="list-style-type: none"> <li>• Haemorrhage</li> <li>• Inflammation and infection</li> <li>• Iron deficiency</li> <li>• Acute haemolytic anaemia</li> <li>• Malignancy</li> <li>• Hyposplenism</li> <li>• Stress e.g. MI, burns</li> <li>• Iatrogenic (corticosteroids, adrenaline, TPO agonists)</li> </ul>

Spurious – microspherocytes, schistocytes, bacteria, pappenheimer bodies, neoplastic cell cytoplasmic fragments

### Investigation

- Important clinical features to ascertain whether there is a secondary cause for the thrombocytosis (see table above)
- Features more suspicious of primary cause include thrombosis (especially if in abdominal vein)/haemorrhage, erythromelalgia, weight loss, sweats and palpable splenomegaly
- Suggest check:

1. ferritin
  2. blood film
  3. CRP
  4. repeat FBC
- If secondary cause found suggest repeat FBC once underlying cause has resolved/been treated
  - If persistent thrombocytosis despite secondary causes excluded or suspicious of primary bone marrow aetiology, suggest referral to clinical haematology

### **MPN-ET (Briefly)**

- Clonal bone marrow disorder with around 50% of cases are positive for mutation in the JAK2 gene (V617F in exon 14). ~10% have MPL (W515K in exon 10) mutation.
- Can manifest systemically with weight loss and sweats as well as bleeding, thrombosis or erythromelalgia.
- Treatment is based on risk stratification for thrombosis. Pharmacological cytoreduction employed with life long 75mg PO OD aspirin.
- There is a risk of progression to myelofibrosis, or transformation to AML in the long term.

### **References**

Guideline for the investigation and management of adults and children presenting with thrombocytosis. Harrison et al. British Journal of Haematology. 2010. 149;3: 352-375